Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Terminated 4Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2Other 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Overweight 1Obesity 1

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Biopsy, Needle × Breast × Clear all
NCT04291950 2022-12-20

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

University of Arizona

Withdrawn
BreastOther

Breast Neoplasms, Obesity, Overweight, Triple Negative Breast Neoplasms

NCT00903214 2013-04-29

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡